ClinicalTrials.govpublic full text
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
bilateral breast carcinoma, her2-negative breast carcinoma, localized breast carcinoma, recurrent breast carcinoma, triple-negative breast carcinoma, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 833610
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.